Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $91.75 in the prior trading day, Boston Scientific Corp (NYSE: BSX) closed at $92.58, up 0.90%. In other words, the price has increased by $0.90 from its previous closing price. On the day, 7.74 million shares were traded. BSX stock price reached its highest trading level at $93.375 during the session, while it also had its lowest trading level at $91.53.
Ratios:
Our goal is to gain a better understanding of BSX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 99.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.89. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.51. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.49.
On September 08, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $125.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $118.Leerink Partners initiated its Outperform rating on June 16, 2025, with a $118 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Butcher Arthur C sold 17,313 shares for $101.55 per share. The transaction valued at 1,758,189 led to the insider holds 23,600 shares of the business.
ARTHUR C BUTCHER bought 17,313 shares of BSX for $1,758,188 on Dec 01 ’25. On Nov 06 ’25, another insider, Zane Ellen M, who serves as the Director of the company, sold 12,891 shares for $98.28 each. As a result, the insider received 1,266,978 and left with 24,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 137244483584 and an Enterprise Value of 148250476544. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.52, and their Forward P/E ratio for the next fiscal year is 26.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.09 while its Price-to-Book (P/B) ratio in mrq is 5.87. Its current Enterprise Value per Revenue stands at 7.662 whereas that against EBITDA is 29.235.
Stock Price History:
The Beta on a monthly basis for BSX is 0.67, which has changed by 0.014260411 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, BSX has reached a high of $109.50, while it has fallen to a 52-week low of $85.98. The 50-Day Moving Average of the stock is -6.28%, while the 200-Day Moving Average is calculated to be -8.51%.
Shares Statistics:
The stock has traded on average 9.93M shares per day over the past 3-months and 9456790 shares per day over the last 10 days, according to various share statistics. A total of 1.48B shares are outstanding, with a floating share count of 1.48B. Insiders hold about 0.39% of the company’s shares, while institutions hold 93.37% stake in the company. Shares short for BSX as of 1764288000 were 18734072 with a Short Ratio of 1.89, compared to 1761868800 on 19453503. Therefore, it implies a Short% of Shares Outstanding of 18734072 and a Short% of Float of 1.27.
Earnings Estimates
Boston Scientific Corp (BSX) is presently subject to a detailed evaluation by 27.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.8, with high estimates of $0.85 and low estimates of $0.75.
Analysts are recommending an EPS of between $3.07 and $2.98 for the fiscal current year, implying an average EPS of $3.03. EPS for the following year is $3.47, with 32.0 analysts recommending between $3.62 and $3.35.
Revenue Estimates
26 analysts predict $5.28B in revenue for. The current quarter. It ranges from a high estimate of $5.33B to a low estimate of $5.25B. As of. The current estimate, Boston Scientific Corp’s year-ago sales were $4.56BFor the next quarter, 26 analysts are estimating revenue of $5.2B. There is a high estimate of $5.31B for the next quarter, whereas the lowest estimate is $5.12B.
A total of 31 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $20.23B, while the lowest revenue estimate was $20.03B, resulting in an average revenue estimate of $20.08B. In the same quarter a year ago, actual revenue was $16.75BBased on 32 analysts’ estimates, the company’s revenue will be $22.38B in the next fiscal year. The high estimate is $23.86B and the low estimate is $22.01B.
